- In clinical trials with LYMPHOSEEK®, no serious hypersensitivity reactions were reported, however LYMPHOSEEK may pose a risk of such reactions due to its chemical similarity to dextran. Serious hypersensitivity reactions have been associated with dextran and modified forms of dextran (such as iron dextran drugs). Prior to the administration of LYMPHOSEEK, patients should be asked about previous hypersensitivity reactions to drugs, in particular dextran and modified forms of dextran. Resuscitation equipment and trained personnel should be available at the time of LYMPHOSEEK administration, and patients observed for signs or symptoms of hypersensitivity following injection.
- Any radiation-emitting product may increase the risk for cancer. Adhere to dose recommendations and ensure safe handling to minimize the risk for excessive radiation exposure to patients or health care workers.
- No serious adverse reactions were reported during clinical trials with LYMPHOSEEK.
- In clinical trials with 553 patients, the most common adverse reactions were:
- Injection site irritation (0.7%; 4 of 553 patients)
- Injection site pain (0.2%; 1 of 553 patients)
- Other adverse reactions were uncommon, and of mild severity and short duration
- Low rate of injection site pain/irritation
- Less than 1% of patients experienced injection site pain or irritation in three well-controlled studies.
- LYMPHOSEEK has no contraindications.
For more information about the safety profile of LYMPHOSEEK, please see full Prescribing Information.
: 1. LYMPHOSEEK Injection [prescribing information]. Dublin, OH: Cardinal Health; June 2017.